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Abstract
Sjogren’s syndrome (SS) is characterized by salivary gland leukocytic infiltrates and impaired
salivation (xerostomia). Cox-2 (Ptgs2) is located on chromosome 1 within the span of the Aec2
region. In an attempt to demonstrate that COX-2 drives antibody-dependent hyposalivation,
NOD.B10 congenic mice bearing a Cox-2flox gene were generated. A congenic line with nonNOD alleles in Cox-2-flanking genes failed manifest xerostomia. Further backcrossing yielded
disease-susceptible NOD.B10 Cox-2flox lines; fine genetic mapping determined that critical Aec2
genes lie within a 1.56 to 2.17 Mb span of DNA downstream of Cox-2. Bioinformatics analysis
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revealed that susceptible and non-susceptible lines exhibit non-synonymous coding SNPs in 8
protein-encoding genes of this region, thereby better delineating candidate Aec2 alleles needed for
SS xerostomia.

1. INTRODUCTION
Sjogren’s syndrome (SS) is an autoimmune disorder characterized by severely impaired
salivary and lachrymal gland function, multiple systemic effects, and a relatively high
incidence of B cell lymphoma [1, 2]. Affected salivary glands show leukocytic infiltrates
characterized by prominent T cell and B cell foci, occasional germinal centers, and
autoantibody-producing plasma cells [1].

NIH-PA Author Manuscript

In both humans and mice with SS, there is strong evidence of a B cell pathogenic role. SS
development is highly linked to overexpression of BAFF [3], a potent B cell survival factor.
Furthermore, in SS-vulnerable NOD mice, B cells are required for age-related
hyposalivation (xerostomia) [4, 5], and in humans with SS, a therapeutic response to B celldepleting Rituximab is reported [6]. AutoAbs to several intracellular e.g. SS-A/Ro and SSB/La, are characteristically generated in this disorder [7, 8]. Xerostomia in both NOD mice
[9, 10] and SS-afflicted humans [11, 12] is linked to pathogenic, class-switched IgG
antibodies that target the M3R muscarinic acetylcholine receptor on salivary gland cells,
impairing acinar cell function. Nonetheless, the cause of xerostomia is undoubtedly
multifactorial.
Th17 inflammatory cells represent a major subset within salivary gland T cell foci of SSafflicted patients and mice [13]. Through synthesis of inflammatory IL-17 and other
cytokines, Th17 cells influence the inflammatory state of the afflicted tissue [14] and
promote the development of Ab-producing germinal centers [15]. The reason why Th17
cells accumulate in SS salivary glands is unclear but may involve heightened expression of
critical cytokines and transcription factors needed for their development and/or expansion
[16, 17]. In addition, it may involve inflammatory lipids, such as arachidonic acid-derived
prostaglandin E2 (PGE2), given that the latter significantly augments Th17 cell expansion
through several routes [18-20].
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In humans, predisposition to SS appears to be multigenic [21] and in NOD (NOD.B10)
mice, spontaneous SS development upon aging depends upon disease susceptibility alleles
located in Chr 1 (Aec2) and Chr 3 (Aec1) [22, 23]. The genes whose allelic differences
determine NOD susceptibility to SS remain unknown. Nevertheless, Nguyen et al. have
gained insights through linking their observations on the disease process with genes located
in narrowed Aec1 and Aec2 regions following the breeding of NOD disease susceptibility
genes onto the C57BL6 genetic background [23, 24]. Genes of possible interest within the
2006-mapped Aec1 locus of B6.Aec1/2 mice encoded IL-2, IL-7, carbonic anhydrase, and
retroviral integration sites [24] while genes of possible interest within the 2008-mapped
Aec2 locus fell into groups involving endogenous viruses and oncogenes, Fas/FasLassociated apoptosis, Th17-associated activities, and lipid/lipoprotein homeostasis [24].
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Recently, we undertook efforts to introduce a floxed Cox-2 (Ptgs2) gene onto the NOD.B10
genetic background for the future purpose of investigating whether B cell-specific COX-2
expression was important for xerostomia development. This was warranted given (a) strong
evidence that COX-2 and downstream PGE2 have a role in regulating the production of
class-switched Abs [25, 26], (b) evidence that cycling B lymphocytes show elevated
synthesis of several PGE2 axis proteins, as well as PGE2 [27, 28], and (c) the above cited
influences of PGE2 on Th17 expansion.
In the present report, we identify a NOD.B10 Cox-2flox-expressing congenic mouse line that
failed to manifest age-related xerostomia, prior to introduction of Cre recombinase. Through
genetic fine mapping, we show the NOD.B10 Cox-2flox congenic mouse exhibits a
replacement of NOD alleles within a recently narrowed Aec2 span [23] that includes the
Cox-2flox allele and flanking Chr 1 genes from a SS non-susceptible genetic background.
Importantly, we demonstrate that genetic alleles strongly influencing SS xerostomia lie
within a significantly more narrowed span of this earlier Aec2 locus. This latter insight came
from identifying novel SS-susceptible mice with recombinations in the region following
further backcrossing. In significantly narrowing the Chr 1 Aec2 span influencing
xerostomia, the study has better delineated the candidate disease susceptibility genes therein.
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2. MATERIALS & METHODS
2.1 Mice and speed congenic breeding
This study was carried out in accordance with the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was approved by the Institutional
Animal Care and Use Committee (IACUC) of The Feinstein Institute for Medical Research
(Project number: 2008-001). NOD.B10Sn-H2b/J: Male and female mice were obtained from
Jackson Labs (Bar Harbor, MA). Cox-2flox/flox: mice bearing a floxed Cox-2 gene on a
mixed 129/B6 background were developed and first described by Ishikawa and Herschman
[29]. Insertion of LoxP sites into introns of the Cox-2 gene has no effect on either baseline
or induced COX-2 expression in mouse macrophages [30].
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Male Cox-2flox/+-bearing founders were crossed with NOD.B10 females and backcrossing
the Cox-2flox gene continued on the NOD.B10 background, at Charles River Laboratories
under contract with the Feinstein Institute. For the first backcross (BC) generation of the
NOD.B10 Cox-2flox/+ congenic lines, F1 females were crossed with male NOD.B10 mice
to fix the Y chromosome as NOD genotype. Thereafter, all subsequent backcross
generations were derived from crossing female NOD.B10 dames with males selected by
speed congenic breeding and genetic testing [31] to possess (a) the Cox-2flox gene and (b)
the greatest homology to NOD.B10 across all autosomal chromosomes. The genetic screen
encompassed 104 microsatellite markers which scanned the 19 autosomal chromosomes at
approximately ~ 15 cM intervals (MAXBAX® speed congenic breeding; Charles River
Laboratories). Additionally, at the second backcross generation, the genetic screen included
a probe for the NOD.B10 MHC alleles. Typically three male mice from each generation
with the greatest NOD homology were chosen for the next backcross to female NOD.B10
mice. After the N5 generation, additional fine mapping involved further microsatellite
markers and single nucleotide polymorphism (SNP) markers that distinguished the NOD and
Clin Immunol. Author manuscript; available in PMC 2015 July 01.
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129 and B6 genetic backgrounds. The screen for the Cox-2flox gene involved testing tailsnip genomic DNA with primers for Cox-2 intron 3 (forward): 5′CTACTGGAGCAGAATGTCCTGTG-3′ and Exon 4 (reverse): 5′ATTGTAAGTAGGTGGACTGTCAATCA –3′ (floxed: ~ 500 bp band; wildtype: ~ 254 bp
band; heterozygous: 500 bp + 254 bp). All genetic testing was performed at Charles River
Laboratories (Troy, NY).
As the backcross generations were established, littermate mice of each generation which had
been identified to lack the Cox-2flox allele were tested as wild-type positive controls for
development of SS, together with NOD.B10 wild-type (WT) mice from Jackson Labs.
C57BL/6J mice (Jackson Labs) were used as negative controls for SS disease. Prior to
testing for salivation, mice had been aged at The Feinstein Institute to at least 5 months of
age.
2.2 Bioinformatics analysis of mouse SNPs in Cox-2 (Ptgs2) and proximal genes in Aec2
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The Mouse Genome Database (MGD) [32] at the Mouse Genome Informatics website, The
Jackson Laboratory, Bar Harbor, Maine. World Wide Web (URL: http://
www.informatics.jax.org) [Nov 2013] and the Mouse Phenome Database at the Jackson
Laboratory (URL: http://phenome.jax.org/) [Jan 2014] were used for mapping microsatellite
and SNP markers and for discerning comparative data on inbred strains: NOD/ShiLtJ,
129S1/SvImJ, and C57BL/6. (While the modified Cox-2flox gene is from the strain 129
background, a screen for C57BL/6 was included due to maintenance on a mixed 129/B6
background.) Each of the above strain designations were scanned for differing SNP alleles
in the gene for Cox-2 (Ptgs2) and protein-encoding genes mapped to later delineated Aec2
regions A, B, and C.
2.3 Salivation Assays
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Upon aging (≥ 5 mo), NOD.B10 mice of both ♂ and ♀ gender characteristically display
hyposalivation [9, 33]. Salivation data were obtained by intraperitoneal ( i.p.) injection with
the muscarinic acetylcholine receptor agonist, pilocarpine (Sigma; St. Louis, MO) at 0.5 μg
per gram body weight. Saliva was collected for a period of 10 minutes with a pipette,
beginning at 2 minutes following pilocarpine injection, using restraint only with no
anesthetic, as described by others [34]. Saliva was transferred into pre-weighed Eppendorf
tubes, which were re-weighed and saliva amount computed as mg per gram mouse weight.
2.4 Assessment of mouse salivary gland histopathology
Submandibular glands from euthanized male and female mice (ranging from 6 to 18 months
of age, as indicated) were excised, fixed in formalin, embedded in paraffin, sectioned, and
stained with H&E. The presence of periductal or perivascular focal lymphocytic
sialoadenitis (FLS) was evaluated by microscopy as previously described [35]. Briefly, the
number of lymphocytic foci was quantified, where a focus represents 50 lymphocytes in a
4mm2 area. The number of focus scores was normalized by dividing the number of foci by
the average area examined for each treatment group, and by measuring the size of individual
foci for each animal. All measurements were made using cellSens Standard software
(Olympus).
Clin Immunol. Author manuscript; available in PMC 2015 July 01.
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Statistical evaluations of measurements within distinctive mouse subgroups were performed
with Excel software; expressed as mean ± SEM; and assessed for significance using a
Student’s t test (unpaired; two-sided. Statistical significance was defined as a p value less
than 0.05).

3.0 RESULTS
3.1 Mapping of recombination sites in novel NOD.B10 congenic mouse lines expressing
Cox-2flox
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A schematic of the speed-congenic backcrossing approach used to develop several
NOD.B10 congenic lines expressing Cox-2flox is illustrated in Figure 1 (and detailed in
Section 2.1). Line A was the first Cox-2flox congenic mouse line identified in the N5
generation of speed-congenic breeding (Table 1). These mice were determined to be > 99%
of NOD genotype; they retained NOD alleles in all genes excepting those in a region of Chr
1 proximal to the floxed Cox-2 gene (Ptgs2) and a distal portion of Chr 16 (devoid of known
disease susceptibility genes). In the N6 generation, Chr 16 was fully NOD while Chr 1,
similarly to the N5 generation, exhibited non-NOD alleles that included the span 133.44 Mb
to 158.26 Mb from the Chr 1 centromere, at a minimum. The non-NOD Chr 1 interval
includes the Cox-2flox gene itself (of strain 129 origin) [29] and proximal genes throughout
the recently narrowed Aec2 disease susceptibility region reported by Nguyen et al. to extend
from D1Mit348 (133.44 Mb) through D1Mit268 (157.36 Mb) [23].
Cox-2flox Line B mice are derived from a further recombination within the Aec2 region,
first detected in the N6 generation of backcrossing Cox-2flox onto NOD.B10 wild-type
females (Table 1). Fine mapping with microsatellite markers and selected SNP markers
confirmed that these mice harbor non-NOD alleles in a shorter span extending from 133.44
Mb through 155.19 Mb from the Chr 1 centromere. Because additional fine mapping
markers were unavailable, the non-NOD region may extend maximally from > 131.66
(outside the recently narrowed Aec2 region [23] ) through < 155.80 Mb. We emphasize that
Line B mice are fully homozygous (HO) for NOD.B10 within the distal portion (155.80
through 157.36 Mb) of the 2008 narrowed Aec2 disease susceptibility region [23] (see later
Figure 3).
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Cox-2flox Line C mice are derived from a still further recombination detected in the N7
generation of backcrossing to NOD.B10 (Table 1). These mice are uniformly NOD.B10
with the exception of a non-NOD region extending from > 144.18 Mb through < 155.19 Mb
from the Chr 1 centromere. (Because fine mapping markers were not available, the nonNOD region maximally could include genes extending from > 139.52 Mb through < 155.80
Mb). We emphasize that Line C mice possess NOD alleles throughout both upstream and
downstream sections of the 2008 narrowed Aec2 region (D1Mit348 at 133.44 Mb through
139.52 Mb) [23] (see later Figure 3).

Clin Immunol. Author manuscript; available in PMC 2015 July 01.
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3.2 Salivation studies in Cox-2flox congenic Lines A, B, and C
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Cox-2flox/+ male mice of the N5 generation or greater were aged to at least 5 months (when
NOD.B10 mice show high penetrance xerostomia, independently of gender [33]) and tested
for saliva formation upon pilocarpine injection. Females and Cox-2flox/flox homozygous
mice were additionally tested in later backcross generations.
Figure 2 shows that the first NOD.B10 Cox-2flox congenic strain developed, Line A,
showed no signs of impaired salivation. The level of pilocarpine-induced salivation in aged
Line A Cox-2flox/+ male mice was significantly greater than that of age and sex-matched,
disease-susceptible NOD.B10 wild-type mice (p = 0.01). Indeed, the amount of saliva
generated from Line A mice was, if anything, greater than that of age and sex-matched
C57BL/6 mice used as negative controls for xerostomia (borderline significance at p = 0.06).
In contrast, as also illustrated in Figure 2, xerostomia was manifest in the two later
NOD.B10 Cox-2flox/+ congenic strains, Line B and Line C, and in Cox-2flox/flox
homozygous Line B The levels of pilocarpine-induced saliva in these latter lines were
indistinguishable from that of wild-type NOD.B10 littermates.
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3.3 Refinement of the Chr 1 Aec2 locus for SS xerostomia
Upon integrating genetic mapping of the above NOD.B10 Cox-2flox congenic lines (Table
1) with past insights on the upstream/downstream borders of the Chr 1 Aec2 locus [23], it
becomes evident that loss of xerostomia in Line A mice can be attributed to a replacement of
NOD alleles with 129 strain alleles throughout the above cited span of the Aec2 locus
(Figure 3). Importantly, Figure 3 also shows that restored xerostomia in Line B and Line C
mice represents regained NOD alleles only within a limited portion of the former mapped
Aec2 locus. The latter is a span inclusive of rs33699657 (155.80 Mb from the Chr 1
centromere) through the end of the 2008-mapped Aec2 region at D1Mit268 (157.36 Mb)
and is designated as “Region B” (Figure 3). Without more refined mapping, it is also
possible that restored NOD alleles within a downstream region designated as “Region A”
could contribute to regained disease. Region A contains genes of undetermined origin in
Lines B and C (Figure 3) and extends from rs262568316 (155.19 Mb) to rs33699657
(155.80 Mb) on Chr 1.
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3.4 Bioinformatics analysis of SNPs within protein-encoding genes in the narrowed Aec2
span
Table 2 provides a list of all protein-encoding genes within the above designated Aec2
subregions A and B. Genes italicized (with one asterisk) express SNP differences between
the NOD and 129 mouse strains in either introns, RNA-UTR, and/or non-synonymous
coding sequences, through bioinformatics analyses described in Section 2.2. Genes in bold
italics (with two asterisks) represent those with at least one non-synonymous coding SNP
that might alter protein function.
We wish to emphasize that the non-synonymous coding SNPs between NOD and the 129
strain do not reflect unique NOD mutations. Rather, NOD SNPs in the genes Cep350,
Tor1aip1, Tor1aip2, Tdrd5, Nphs2, and Axdnd1 are shared with several other mouse strains
that do not develop spontaneous SS upon aging, e.g. A/J, AKR/J, BALB/cJ, C3H/HeJ,
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CBA/J and DBA/2J (as determined by the MPD database (http://phenome.jax.org/)).
Furthermore, the non-synonymous coding SNPs that distinguish NOD and 129 within the
genes for Tor3a and Abl2 are shared between NOD and a differing set of mouse strains, e.g.
C57BL/6J and C57BL/6NJ. Thus, the Chr 1 Aec2 locus of NOD appears to represent a
recombination between two major mouse lineages.
3.5 Evidence for sialadenitis (inflammatory foci within salivary glands) in all NOD.B10
Cox-2flox congenic strains
Infiltrates of mononuclear cells within salivary glands are quite characteristic of SS.
Nevertheless, in both mice and humans, the extent of lymphocytic infiltration is not always
concordant with clinical evidence of xerostomia [4, 36]. A similar lack of concordance was
evidenced in this study. While NOD.B10 wt and congenic Cox-2flox/+ Line A differed
significantly in saliva output upon aging (Figure 2A), the submandibular salivary glands of
nearly all examined mice showed evidence of sialadenitis (periductal leukocyte infiltration;
white arrows) (Figure 4C: Cox-2flox/+ Line A and Figure 4D and E: Cox-2flox/flox Line B).
Given the limited numbers of Cox-2flox/+ Line A mice available for study, we cannot
eliminate the possibility that differences may have emerged with larger cohorts.

NIH-PA Author Manuscript

Figure 5 presents a quantitative comparison of the inflammatory infiltrates detected within
the novel Cox-2flox congenic lines here studied, as compared to wild-type NOD.B10
controls. Regardless of whether measurements were made of the number of foci per
submandibular lobe (Figure 5A), foci per mm2 of gland (Figure 5B), or size of foci in mm2
(Figure 5C), no significant differences were noted between NOD.B10 WT and NOD.B10
Cox-2flox/+ Line A or Cox-2flox/+ or Cox-2flox/flox Line B. At the time of the salivary
gland study, adequately aged NOD.B10 Cox-2flox Line C mice were not available, but given
that the latter have greater homology with NOD.B10 WT than do Line B, differences
between Line C and WT are not anticipated. Of note, in both Cox-2 WT and Cox-2flox/+
Line B mice, a trend toward greater focal frequency in females over males was observed;
however, this difference did not reach statistical significance.

4.0 DISCUSSION
NIH-PA Author Manuscript

In an effort to introduce a floxed Cox-2 (Ptgs2) gene into the genetic background of SSsusceptible NOD.B10 mice, we have narrowed the candidate genes within Chr 1 which
influence SS xerostomia in mice. Important to this development is the fact that the Cox-2
gene resides within an earlier reported Aec2 span [24].
Through genetic mapping of Chr 1 in xerostomia-resistant NOD.B10 Cox-2flox/+ Line A
mice, we confirmed an earlier report of Nguyen et al. that predisposing alleles resided within
a region extending from 133.44 Mb (D1Mit348) through 157.36 Mb (D1Mit268)
downstream of the Chr 1 centromere [23]. Nguyen et al. found this region important through
breeding NOD susceptibility genes onto a non-susceptible C57BL/6 genetic background
[23]. Conversely, we discerned its relevance by noting a loss of xerostomia when Cox-2flox
and flanking genes (from non-susceptible mouse strain 129) were backcrossed onto the
susceptible NOD.B10 background. The fact that this region was found critical through
opposing approaches reinforces its relevance to SS. Furthermore, our finding that Line A
Clin Immunol. Author manuscript; available in PMC 2015 July 01.
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mice, which were heterozygous (HET) for Cox-2flox, manifest xerostomia-resistance
showed that protection from this disease manifestation does not require homozygosity (HO)
of the non-NOD alleles.
Of note, further fine genetic mapping of Chr 1 in the above Line A mice and in two later
xerostomia-susceptible congenic lines enabled us to narrow the Chr 1 Aec2 alleles affecting
SS hyposalivation to a DNA region spanning 1.56 to 2.17 Mb on Chr 1. We excluded a
relatively large segment from the above 2008-mapped Aec2 locus [23]. The omitted
segment maps from D1Mit348 (133.44 Mb) through rs262568316 (155.19 Mb) and includes
the Cox-2 gene which begins at 150.10 Mb. The basis for exclusion was evidence that both
HET and HO Cox-2flox Line B mice (possessing non-NOD alleles in the latter span)
developed SS xerostomia comparable to that noted in NOD.B10 wild-type mice. We want to
emphasize the point that elimination of Cox-2 and closely flanking genes as disease
susceptibility genes (on the basis of alleles represented) does not mean that proteins encoded
by these genes are irrelevant to SS. Rather, it means that there are no allelic differences
which make one allele significantly more likely to cause this disease than another.
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A possibility that cannot be presently precluded is that the above omitted span contains
genes whose alleles influence the age at which xerostomia becomes manifest. Most of the
mice here evaluated for xerostomia were substantially older than the past noted age
threshold xerostomia development, ~ 17 to 24 months of age [37]. In their study of 39
recombinant inbred lines generated from crossing C57BL/6.NOD-Aec1Aec2 mice with
C57BL/6J mice, Nguyen et al. had suggested that quantitative trait loci (QTL) may be
present at the centromeric end of their 2008-mapped Aec2 locus [23].
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The region presently defined as Aec2 Region B (between155.80 Mb and 157.36 Mb) appears
most likely to contain the Chr 1-localized genes whose alternative alleles strongly influence
SS xerostomia. This conclusion is based on three factors: (a) past mapping which showed
that the most downstream end of Aec2 extends to D1Mit268 (157.36 Mb) [23]; (b) the
current study’s finding that Line A mice, which failed to develop xerostomia, lacked NODderived genes throughout Region B, whereas disease-susceptible Lines B and C possessed
NOD alleles in this region; and (c) a bioinformatics search which showed that nearly all
Region B protein-encoding genes express SNPs that distinguish the NOD and 129 mouse
strains. Interestingly, of 16 protein-encoding genes in this region, 14 genes (88%) expressed
differing SNPs in introns or RNA UTR regions and/or expressed non-synonymous coding
SNPs. Eight genes (50%) displayed non-synonymous exon SNPs that could influence
protein structure and /or function.
Region B genes with non-synonymous coding SNPs included Cep350, Tor1aip1 (LAP),
Tor1aip2 (LULL1), Tdrd5, Nphs2 (podocin), Axdnd1, Abl2, and Tor3a. Cep350 is of
particular interest in the context of SS. This gene encodes CAP350 [38], a centrosome- and
microtubule-associating protein that is not extensively studied but is reported to directly
engage and compartmentalize the PPAR group of nuclear hormone receptors, PPARα and
PPARγ, within cell nuclei [39]. Interestingly, PPARs are linked to the COX-2/PGE2 axis
[40] and known to strongly influence lipid metabolism, autoimmunity, and Th1 and Th17
subset development, in a sex-hormone-determined fashion [16, 41, 42]. CAP350
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engagement with PPARα was reported to sequester the latter in a subnuclear compartment
and compromise its function as a transactivator [39]. Whether PPARγ is similarly regulated
is unknown. It will be of interest to compare the expression/function of CAP350 protein
from NOD mice and SS-resistant mice expressing the diverse Cep350 coding SNPs.
Another intriguing Region B gene found to manifest non-synonymous coding SNPs is
Tor3a (also known as ADIR). In humans this gene is primarily expressed in salivary glands,
lymph nodes, and stomach, but in mice its expression is more widespread [43]. The
characterizations of Tor3a as an IFN-α-responsive gene [43], and SS as a disease with a
strong IFN-α signature in both mice and humans [44, 45], suggest that Tor3a levels should
be elevated in SS. Indeed, heightened levels of this protein are found in exosomes from
human parotid gland saliva [46] as well as in PHA-activated T lymphoblasts, EBVtransformed B lymphoblasts and several B cell malignancies [47]. The Tor3a gene encodes
an ER protein with 8 potential phosphorylation sites; coding SNPs might affect the potential
for these modifications. Another intriguing attribute of Tor3a is its status as a minor
histocompatibility molecule [47]. Conceivably, aspects of its structure could promote
autologous T cell activation [48], particularly if triggering thresholds are altered by
inflammatory changes within salivary gland tissues.
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Five remaining genes within Region B with non-synonymous coding SNPs that distinguish
NOD and 129 also warrant discussion. Abl2, encodes Arg, an F-actin-binding kinase that
overlaps in function with Abl1, a related kinase with a critical role in lymphocyte
development and signaling [49, 50]. Tor1aip1 (LAP11) and Tor1aip2 (LULL1), two
neighboring genes, encode proteins which regulate the activity of Torsin A, an cytoplasmic
ATPase [51, 52] that is linked to the nuclear skeleton, cell cycle, and lamins [53]. Axdnd1
(axonemal dynein light chain domain containing 1) encodes a microtubule-binding protein
with a role in intracellular transport. The two remaining genes with non-synonymous coding
SNPs, Tdrd5 (tudor domain containing 5) and Nphs2 (podocin), appear less relevant to SS.
Nphs2 (podocin) is restricted to the kidney and Tdrd5 is an RNA-binding protein thought to
function primarily in maintaining germline integrity during spermatogenesis.
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While not manifesting coding SNPs, three other Region B genes express intron and RNAUTR SNPs that might affect mRNA synthesis, splicing and/or stability. The Qsox1 gene
encodes two major quiescin sulfydryl oxidase 1 protein isoforms that are a consequence of
differential RNA splicing. Qsox1 proteins function in secretion, cell anchorage, and the
regulation of cell oxidative stress and proliferation [54]; are present in salivary glands
(http://www.proteinatlas.org/ENSG00000116260/tissue); and are elevated in certain
malignancies [54]. Soat1 is a sterol O-acyltransferase recently defined as a quantitative trait
locus gene for hyperlipidemia [55] and was previously implicated as an Aec2 lipid
regulatory gene by Nguyen et al. on the basis of abnormal lipid accumulations in the
salivary and lachrymal glands of SS-afflicted mice [23, 56]. Finally Rasal2, encodes a
RasGAP family member which negatively regulates Ras function and whose deletion/
mutation promotes tumor metastasis [57].
Although the additional Aec2 span defined as Region A is located within the broad Aec2
span mapped earlier by Nguyen et al. [23], the unavailability of fine mapping markers
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precluded us from discerning whether alleles of Region A genes were of NOD or 129 origin.
Bioinformatics analysis of the three protein-encoding genes present revealed that only one
gene, Acbd6, expressed SNPs that distinguish NOD and 129. While the SNPs within this
gene (encoding a cytoplasmic lipid, Acyl-CoA-binding protein [58]) do not affect exons,
they might affect mRNA synthesis or stability.
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Although the Cox-2 gene possesses no SNPs that distinguish NOD and 129, the gene’s
location at the center of the Aec2 disease susceptibility region [23] could be of significance.
COX-2 is a critical modulator of PGE2 which, among its diverse functions, can mediate
epigenetic changes through regulating the transcription of DNA methyltransferases,
DNMT1, DNTM3a, and DNTM3b [59, 60]. Thus, there is an intriguing possibility that
COX-2-regulated PGE2 influences the expression of proximal genes. Indeed, PGE2 has
positive forward effects on Cox-2 gene transcription [61, 62], but whether a change in the
gene’s methylation status [63] is involved is unclear. Other evidence that genes in physical
proximity often show functional linkage and are co-transcribed [64, 65] is consistent with
such a COX-2 regulatory role. The fact that many genes in the genetic block extending from
133.603 to 157.140 Mb of mouse Chr 1 show shared synteny between mice and humans
(http://www.animalgenome.org/VCmap/) suggests that there may be evolutionary pressure
to retain their proximity.
In summary, through narrowing the Aec2 span with a strong effect on xerostomia, this study
has correspondingly narrowed the candidate disease susceptibility genes for this SS disease
manifestation. Based on available information, we consider the most notable among these to
be the genes encoding CAP350, a centriole and nucleus-associated protein that engages
several members of the important PPAR nuclear receptor family; Tor3a (ADIR), an IFN-αupregulated protein which encodes a minor histocompatibility antigen expressed in normal
salivary glands and activated lymphocytes; Abl2 (Arg), an Abl1-related kinase; Tor1aip1
(LAP11) and Tor1aip2 (LULL1), important regulatory proteins of the cytoplasmic
ATPase, Torsin-A; and Qsox1, a salivary gland-expressed protein with roles in secretion,
cell anchorage, proliferation, and regulation of oxidative stress. With better tools for
resolving the importance of these genes and their products, and COX-2 as well, improved
therapies to control a disorder afflicting millions of women over the age of 50 may be
realized.
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∎ SS-susceptible NOD.B10 mice with a floxed Cox2 (Ptgs2) gene in Chr 1 are
identified
∎ Candidate Chr 1 Aec2 genes affecting SS hyposalivation (xerostomia) are narrowed
∎ Susceptibility alleles are downstream of Ptgs2 and within a 1.56 to 2.17 Mb span of
DNA
∎ Narrowed Aec2 span contains 8 genes with non-synonymous coding SNPs
∎ The latter genes encode proteins with roles in immunity and cell proliferation
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FIGURE 1. Schematic for development of NOD.B10 congenic mouse lines expressing Cox-2flox

MAX-BAX® speed congenic breeding was used to backcross a Cox-2flox gene onto the
NOD.B10 genetic background (Section 2.1). Line A Cox-2flox/+ mice tested below for
salivation and sialadenitis derived from the 5th and 6th backcross generation; Tested Line B
Cox-2flox/+ and Cox-2flox/flox mice were derived from an F1 cross between the Cox-2flox/+
heterozygous offspring of the 6th backcross generation. Tested Line C Cox-2flox/+ mice
were derived from an F1 cross of the heterozygous offspring from an 8th backcross
generation.
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FIGURE 2. Aged NOD.B10 Cox-2flox/+ Line A mice do not manifest hyposalivation
(xerostomia), while aged Cox-2flox/+ and Cox-2flox/flox Line B and Cox-2flox/+ Line C mice do
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As aged mice of NOD.B10 Cox-2flox Lines A, B, and C became available throughout the
backcrossing process, they were tested for salivation by i.p. injection of pilocarpine, a nonselective muscarinic receptor agonist. In testing Line A, comparisons were made to both age
and sex matched NOD.B10 wild-type mice (+ control for xerostomia) and C57BL/6 mice
(neg control for xerostomia). In later examination of Lines B and C, comparisons were made
to age and sex-matched backcross littermates which did not express the Cox-2flox gene.
HET = heterozygosity for Cox-2flox; HO = homozygosity for Cox-2flox; WT = wild-type
NOD.B10 for Cox-2. Plotted values represent amount of saliva obtained (mean weight in mg
± SEM) within each group. P values of statistical significance (<0.05) are indicated by an
asterisk. The findings that saliva levels in Line A were significantly greater than NOD.B10
WT mice, and even exceeded levels in negative control C57BL/6 mice (albeit not at a level
of statistical significance) indicate that Line A lacks the Aec2 alleles needed for
development of SS xerostomia. The finding that the saliva levels measured in Line B mice
(HET and HO) are not significantly different from NOD.B10 Cox-2 WT littermates
indicates that genes spanning the region 134.2 to 153.7 Mb from the Chr 1 centromere do
not display allelic differences that control the development of SS xerostomia.
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FIGURE 3. Schematic of regions of recombination in mouse chromosome 1 within novel
NOD.B10 Cox-2flox congenic lines developed by backcrossing Coxflox onto SS-susceptible
NOD.B10 genetic background

The major Chr 1 mapping markers used for fine mapping are shown, as well as their location
in cM or as Mb from the Chr 1 centromere (based on recent NCBI Build 38 [32]). Regions
mapping definitively as NOD genotype are shown in grey; regions with genes that are
definitively not-NOD are shown in black; regions of unknown origin are shown hatched.
The bar to the right shows the span of the Aec2 locus, as mapped in 2008 by Nguyen et al.
[23]. The salivation assessments of Lines A, B, and C in Figure 2 show that allelic
differences in genes spanning 133.44 to 155.19 Mb do not determine SS disease
susceptibility in mice. Region B likely contains SS pre-disposing alleles and Region A may
as well. These SS candidate alleles are listed in Table 2.
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FIGURE 4. Periductal leukocyte infiltrates are present within salivary glands of aged
Cox-2flox/+ (HET) Line A mice (no xerostomia) and Cox-2flox/+ and Cox-2flox/flox (HO) Line B
mice (with xerostomia)

Submandibular salivary glands were excised from aged NOD.B10 wild-type male (M) and
female (F) mice, as well as male mice of congenic Cox-2flox Line A or Line B. Tissue was
immediately fixed and paraffin-embedded. Sliced, H&E stained tissues were viewed and
photographed at an original magnification of 200X. In each case, an effort was made to
photograph a section containing a typical infiltrate (shown by white arrows). The section in
F, representing a salivary gland from a Line B homozygous (HO) mouse did not exhibit any
foci, whereas foci were clearly evidenced in Line B HO mice shown in D and E.
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FIGURE 5. Neither frequency nor size of leukocytic foci differ significantly between aged
NOD.B10 wild-type mice and congenic NOD.B10 Cox-2flox/+ or Cox-2flox/flox Line B mice

Efforts were made to quantify sialadenitis in the mice under study through comparisons of
(A) the number of foci per submandibular lobe; (B) the number of foci per mm2 of gland
and (C) the size of each infiltrate in mm2. Shown are the mean ± SEM values for mice of
each group. In the case of NOD.B10 Cox-2flox/+ Line A, values for the single mouse (10
mo of age) are shown. Values for all NOD.B10 WT were pooled according to gender; ages
of the males and females at the time of salivary gland excision ranged from 8-18 months
(males) and 8-10 months (females). Salivary glands from congenic Cox-2flox line B mice
were obtained at the following ages: flox/+ HET males (5-8 mo); flox/flox HO males (8
mo); and HET females (10 mo). (Note: in measuring size, infiltrates were not reliably
measured if they were less than 0.01 mm2. For the purposes of calculation, the latter were
nevertheless given a score of 0.01, and this may have slightly inflated the average size of
infiltrates.) Statistical analyses indicated no significant statistical difference between any test
group and its respective WT, within each gender group.
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Mapping of CHR 1 recombination sites in NOD.B10 COX-2flox congenic lines
CHR

Marker ID

cM

Mb

N5 GENERATION

N6 GENERATION

N7 GENERATION

(NCBI Build 36)

LINE A

LINE A

LINE B

LINE B

LINE C

1

D1Mit430
to D1Mi46

4.3
−39.16

14.28
−75.57

NOD

NOD

NOD

NOD

NOD

1

D1Mit308

50.78

110.60

NOD

NOD

NOD

NOD

NOD

1

D1Mit218

55.76

127.44

NOD

NOD

NOD

NOD

NOD

131.96

NOD

NOD

133.44

129

NOD

1

rs4222623

1

D1Mit348

1

rs30881422

134.16

129

NOD

1

rs30882302

134.19

129

NOD

57.92
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1

rs13476119

134.21

129

NOD

1

rs13476121

134.67

129

NOD

1

rs6279930

137.37

129

NOD

1

rs13476138

139.52

129

NOD

1

rs3722434

1

D1Mit102

144.18
63.32

129

129

147.24

129

129

129

129

129

1

Ptgs-2-flox

63.84

150.10

129

129

129

129

129

1

D1Mit501

64.93

152.62

129

129

129

129

129

1

D1Mit396

65.26

153.12

129

129

1

D1Mit104

65.42

153.68

129

129

1

rs13476185

153.71

129

129

1

rs221940485

155.05

129

129

1

rs262568316

155.19

129

129

1

rs33699657

155.80

NOD

NOD
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1

rs32202210

NOD

NOD

1

D1Mit451

67.67

155.84
155.96

129

129

NOD

NOD

NOD

1

D1Mit425

67.71

156.62

129

129

NOD

NOD

NOD

1

D1Mit14

67.71

156.77

129

1

D1Mit290

68.05

157.95

129

1

D1Mit227

68028

158.26

129

1

D1Mit507

72.38

165.04

NOD

NOD

NOD

NOD

NOD

1

CRP

80.13

172.69

NOD

NOD

NOD

NOD

NOD

1

D1Mit362

94.35

189.25

NOD

NOD

NOD

NOD

NOD

1

D1Mit17

95.03

189.57

NOD

NOD

NOD

NOD

NOD

a

N5 generation mice were fully NOD in all other chromosomes (> 99% congenic) on the basis of full autosomal chromosome screen with
micorsatellite markers.
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Protein-encoding genes encoded within presently narrowed Aec2 sub-regions in Chr 1

Region A

Region B

Mb from
centromere a

Gene

155.275

Xpr1, xenotropic and polytropic retrovirus receptor 1

155.558 *

Acbd6, acyl-Coenzyme A binding domain containing 6

155.698

Lhx4, LIM homeobox protein 4

155.778 *

Qsox1, quiescin Q6 sulfhydryl oxidase 1

155.844 **

Cep350, centrosamal protein 350 (CAP350)

156.006 **

Tor1aip1, torsin A interacting protein 1 (LAP1)

156.035 **

Tor1aip2, torsin A interacting protein 2 (LULL1)

156.075

Fam163a, family with sequence similarity 163, member A

156.255 **

Tdrd5, tudor domain containing 5

156.310 **

Nphs2, nephrosis 2 homolog, podocin (human)

156.323 **

Axdnd1, axonemal dynein light chain domain containing 1

156.428 *

Soat1, sterol O-acyltransferase 1
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156.558 **d

Abl2, Abetson murine leukemia viral oncogene homolog 2

156.653 **

Tor3a, torsin family 3, member A (ADIR)

156.678 *

Fom20b, family with sequence similarity 20, member B

156.804 *

Rolgps2, Ral GEF with PH domain and SH3 binding motif 2

156.838 *

Angptl1, angiopoietin-like 1

157.099

Tex35, testis expressed 35

157.140 *

Rosal2, RAS protein activator like 2

a

Chr 1 position based on GRCm36 genome coordinates (MGD database: (URL: http://www.informatics.jax.org) [Nov 2013]

b

One asterisk and italics indicates SNP differences between NOD and 129 in introns and/or RNA-UTR, as determined by the MGD mouse SNP
database above.
c

Two asterisks and bold italics indicates that in addition to the above SNP differences, the gene displays one or more non-synonymous coding SNP
differences between NOD & 129.
d

An Abl2 gene non-synonymous coding SNP (rs30466582) is reported in the MPD, but not MGD database.
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